Drugs / Ultrase® MT20
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00513682 | Jul 2007 → Mar 2008 | cystic fibrosis, exocrine pancreatic insufficiency | Forest Laboratories | Completed | Met primary |
| Phase 3 | NCT00408317 | Nov 2006 → Apr 2007 | cystic fibrosis, exocrine pancreatic insufficiency | Forest Laboratories | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ultrase MT 20 | “Ultrase® MT 20 capsules orally daily for 6 to 7 days in either first intervention period or second intervention period.” NCT00408317 ↗ |
| Modality | Protein / enzyme biologic | “Pancreatic enzyme product” NCT00408317 ↗ |
| Route | Oral | “containing enteric-coated minitablets orally daily” NCT00408317 ↗ |